Cargando…

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

BACKGROUND: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin). METHODS: Patients had histologically or cyto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Xinan, Yan, Xieqiao, Chi, Zhihong, Cui, Chuanliang, Si, Lu, Tang, Bixia, Li, Siming, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Zhou, Li, Kong, Yan, Dai, Jie, Ding, Lieming, Mao, Li, Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184160/ https://www.ncbi.nlm.nih.gov/pubmed/32335374 http://dx.doi.org/10.1016/j.ebiom.2020.102755

Ejemplares similares

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

A nomogram incorporating Ki67 to predict survival of acral melanoma
por: Du, Yu, et al.
Publicado: (2023)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
por: Zhou, Li, et al.
Publicado: (2022)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
por: Bai, Xue, et al.
Publicado: (2021)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
por: Sheng, Xinan, et al.
Publicado: (2019)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
por: Mao, Lili, et al.
Publicado: (2021)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Surgical Outcomes of Vaginal or Cervical Melanoma
por: Tian, Hui, et al.
Publicado: (2022)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
por: Tang, Bixia, et al.
Publicado: (2019)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study
por: Gao, Yunxia, et al.
Publicado: (2023)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
por: Dai, Jie, et al.
Publicado: (2017)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats
por: Ren, Chengda, et al.
Publicado: (2017)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2019)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2023)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non‐small cell lung cancer in vitro and in vivo
por: Zhang, Kun, et al.
Publicado: (2020)

Status of FPP Project D-082
por: Allardyce, B W
Publicado: (1994)

Serum Fat-Soluble Vitamin Levels of 6,082 Minors in Zhuzhou City
por: Tang, Qiong, et al.
Publicado: (2022)

Title unknown, CERN-ALEPH-99-082
por: CERN. Geneva. ALEPH
Publicado: (1999)

MON-082 The Neonatal Screen That Cried Wolff
por: D’Ambrosio, Fabiola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lhv14ikbtbjbj7kc8sngomeper